Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket - PubMed (original) (raw)
. 2008 Jan 15;18(2):767-71.
doi: 10.1016/j.bmcl.2007.11.043. Epub 2007 Nov 17.
Derek C Cole, Joseph R Stock, Mohani N Sukhdeo, John W Ellingboe, Rebecca Cowling, Guixian Jin, Eric S Manas, Kristi Y Fan, Michael S Malamas, Boyd L Harrison, Steve Jacobsen, Rajiv Chopra, Peter A Lohse, William J Moore, Mary-Margaret O'Donnell, Yun Hu, Albert J Robichaud, M James Turner, Erik Wagner, Jonathan Bard
Affiliations
- PMID: 18068983
- DOI: 10.1016/j.bmcl.2007.11.043
Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket
Lee D Jennings et al. Bioorg Med Chem Lett. 2008.
Abstract
The proteolytic enzyme beta-secretase (BACE-1) produces amyloid beta (Abeta) peptide, the primary constituent of neurofibrillary plaques, implicated in Alzheimer's disease, by cleavage of the amyloid precursor protein. A small molecule inhibitor of BACE-1, (diaminomethylene)-2,5-diphenyl-1H-pyrrole-1-acetamide (1, BACE-1 IC(50)=3.7 microM), was recently described, representing a new small molecule lead. Initial SAR investigation demonstrated the potential of accessing the nearby S(3) and S(1)(') substrate binding pockets of the BACE-1 enzyme by building substituents off one of the phenyl substituents and guanidinyl functional group. We report here the optimization of guanidinyl functional group substituents on 1, leading to potent submicromolar BACE-1 inhibitors.
Similar articles
- Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets.
Cole DC, Stock JR, Chopra R, Cowling R, Ellingboe JW, Fan KY, Harrison BL, Hu Y, Jacobsen S, Jennings LD, Jin G, Lohse PA, Malamas MS, Manas ES, Moore WJ, O'Donnell MM, Olland AM, Robichaud AJ, Svenson K, Wu J, Wagner E, Bard J. Cole DC, et al. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1063-6. doi: 10.1016/j.bmcl.2007.12.010. Epub 2007 Dec 10. Bioorg Med Chem Lett. 2008. PMID: 18162398 - Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta.
Bakshi P, Jin C, Broutin P, Berhane B, Reed J, Mullan M. Bakshi P, et al. Bioorg Med Chem. 2009 Dec 1;17(23):8102-12. doi: 10.1016/j.bmc.2009.09.051. Epub 2009 Oct 3. Bioorg Med Chem. 2009. PMID: 19853461 - Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS. Martone RL, et al. J Pharmacol Exp Ther. 2009 Nov;331(2):598-608. doi: 10.1124/jpet.109.152975. Epub 2009 Aug 11. J Pharmacol Exp Ther. 2009. PMID: 19671883 - Progress toward the discovery and development of efficacious BACE inhibitors.
Durham TB, Shepherd TA. Durham TB, et al. Curr Opin Drug Discov Devel. 2006 Nov;9(6):776-91. Curr Opin Drug Discov Devel. 2006. PMID: 17117686 Review. - Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T. Tomita T. Expert Rev Neurother. 2009 May;9(5):661-79. doi: 10.1586/ern.09.24. Expert Rev Neurother. 2009. PMID: 19402777 Review.
Cited by
- The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.
Butini S, Brogi S, Novellino E, Campiani G, Ghosh AK, Brindisi M, Gemma S. Butini S, et al. Curr Top Med Chem. 2013;13(15):1787-807. doi: 10.2174/15680266113139990137. Curr Top Med Chem. 2013. PMID: 23931442 Free PMC article. Review. - Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?
Robles A. Robles A. Open Neurol J. 2009 Apr 2;3:27-44. doi: 10.2174/1874205X00903010027. Open Neurol J. 2009. PMID: 19461897 Free PMC article. - Developing β-secretase inhibitors for treatment of Alzheimer's disease.
Ghosh AK, Brindisi M, Tang J. Ghosh AK, et al. J Neurochem. 2012 Jan;120 Suppl 1(Suppl 1):71-83. doi: 10.1111/j.1471-4159.2011.07476.x. Epub 2011 Nov 28. J Neurochem. 2012. PMID: 22122681 Free PMC article. Review. - The β-secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid-β reduction to downstream disease-relevant effects.
Neumann U, Machauer R, Shimshek DR. Neumann U, et al. Br J Pharmacol. 2019 Sep;176(18):3435-3446. doi: 10.1111/bph.14582. Epub 2019 Mar 10. Br J Pharmacol. 2019. PMID: 30657591 Free PMC article. Review. - Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease.
Kulshreshtha A, Piplani P. Kulshreshtha A, et al. Neurol Sci. 2016 Sep;37(9):1403-35. doi: 10.1007/s10072-016-2625-7. Epub 2016 Jun 1. Neurol Sci. 2016. PMID: 27250365 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Chemical Information
Miscellaneous